Literature DB >> 23770857

Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer.

L Liu1, H-X Xu1, W-Q Wang1, C-T Wu1, T Chen1, Y Qin1, C Liu1, J Xu1, J Long1, B Zhang1, Y-F Xu1, Q-X Ni1, M Li2, X-J Yu1.   

Abstract

Caveolin-1 exhibits a stage-dependent, functional fluctuation during pancreatic cancer development, but the underlying mechanisms remain unclear. Here, we report that cavin-1, a structural protein of caveolae, modulates the oncogenic function of caveolin-1 and cooperates with caveolin-1 to enhance pancreatic cancer aggressiveness. Cavin-1 expression is associated with caveolin-1 in pancreatic cancer tissue samples and cell lines, and predicts the metastatic potential of pancreatic cancer. Interactome analyses further revealed the physical interaction of cavin-1 and caveolin-1 and their colocalization in pancreatic cancer cells. Cavin-1 stabilizes caveolin-1 expression or activity by inhibiting its internalization and subsequent lysosomal degradation. More in-depth functional experiments showed that caveolin-1-enhanced aggressiveness of pancreatic cancer cells is dependent on the presence of cavin-1. In contrast, cavin-1 depletion inhibited the invasion and metastasis of pancreatic cancer cells, which could not be restored by caveolin-1-rescue construct. Tissue microarray analyses in two independent clinic cohorts also supported the augment of cavin-1 on the prognostic potency of caveolin-1, and showed that combination of cavin-1 with caveolin-1 predicted worse survival in pancreatic cancer patients. Of note, the phenotypes because of cavin-1 could not be achieved by other cavins such as cavin-2, and the tumor-promoting role of cavin-1 in pancreatic cancer was found to be largely dependent on caveolin-1 expression, which highlights the critical role of cavin-1/caveoin-1 in pancreatic cancer progression, and suggests that the interruption of cavin-1/caveolin-1 interaction is a promising therapeutic strategy for pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770857     DOI: 10.1038/onc.2013.223

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Rab5 is required in metastatic cancer cells for Caveolin-1-enhanced Rac1 activation, migration and invasion.

Authors:  Jorge Díaz; Pablo Mendoza; Rina Ortiz; Natalia Díaz; Lisette Leyton; Dwayne Stupack; Andrew F G Quest; Vicente A Torres
Journal:  J Cell Sci       Date:  2014-03-21       Impact factor: 5.285

2.  Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.

Authors:  Fiorella Faggi; Nicola Chiarelli; Marina Colombi; Stefania Mitola; Roberto Ronca; Luca Madaro; Marina Bouche; Pietro L Poliani; Marika Vezzoli; Francesca Longhena; Eugenio Monti; Barbara Salani; Davide Maggi; Charles Keller; Alessandro Fanzani
Journal:  Lab Invest       Date:  2015-03-30       Impact factor: 5.662

3.  Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients.

Authors:  Qing Guo; Ge-Fei Guan; Wen Cheng; Cun-Yi Zou; Chen Zhu; Peng Cheng; An-Hua Wu
Journal:  CNS Neurosci Ther       Date:  2018-10-11       Impact factor: 5.243

4.  Expression of the Cavin Family in Childhood Leukemia and Its Implications in Subtype Diagnosis and Prognosis Evaluation.

Authors:  Jing Yang; Junbin Huang; Huabin Wang; Yong Liu; Yanlai Tang; Chao Lin; Qin Zhou; Chun Chen
Journal:  Front Pediatr       Date:  2022-06-03       Impact factor: 3.569

5.  Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Authors:  Hua-Xiang Xu; Tao Chen; Wen-Quan Wang; Chun-Tao Wu; Chen Liu; Jiang Long; Jin Xu; Ying-Jian Zhang; Run-Hao Chen; Liang Liu; Xian-Jun Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-13       Impact factor: 9.236

6.  Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer.

Authors:  Moumita Chatterjee; Edgar Ben-Josef; Dafydd G Thomas; Meredith A Morgan; Mark M Zalupski; Gazala Khan; Charles Andrew Robinson; Kent A Griffith; Ching-Shih Chen; Thomas Ludwig; Tanios Bekaii-Saab; Arnab Chakravarti; Terence M Williams
Journal:  Sci Rep       Date:  2015-06-12       Impact factor: 4.379

7.  PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis.

Authors:  Zeyad D Nassar; Hyeongsun Moon; Tam Duong; LiQi Neo; Michelle M Hill; Mathias Francois; Robert G Parton; Marie-Odile Parat
Journal:  Oncotarget       Date:  2013-10

8.  Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.

Authors:  Fiorella Faggi; Stefania Mitola; Guglielmo Sorci; Francesca Riuzzi; Rosario Donato; Silvia Codenotti; Pietro Luigi Poliani; Manuela Cominelli; Raffaella Vescovi; Stefania Rossi; Stefano Calza; Marina Colombi; Fabio Penna; Paola Costelli; Ilaria Perini; Maurilio Sampaolesi; Eugenio Monti; Alessandro Fanzani
Journal:  PLoS One       Date:  2014-01-10       Impact factor: 3.240

9.  The clinicopathological significance of miR-133a in colorectal cancer.

Authors:  Timothy Ming-Hun Wan; Colin Siu-Chi Lam; Lui Ng; Ariel Ka-Man Chow; Sunny Kit-Man Wong; Hung-Sing Li; Johnny Hon-Wai Man; Oswens Siu-Hung Lo; Dominic Foo; Alvin Cheung; Thomas Yau; Jensen Tung-Chung Poon; Ronnie Tung-Ping Poon; Wai-Lun Law; Roberta Wen-Chi Pang
Journal:  Dis Markers       Date:  2014-07-01       Impact factor: 3.434

10.  Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer.

Authors:  J Li; D Gu; S S-Y Lee; B Song; S Bandyopadhyay; S Chen; S F Konieczny; T L Ratliff; X Liu; J Xie; J-X Cheng
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.